TransCode Therapeutics, Inc. (RNAZ)
NASDAQ: RNAZ · Real-Time Price · USD
9.55
-0.13 (-1.34%)
At close: Mar 18, 2026, 4:00 PM EDT
9.22
-0.33 (-3.46%)
After-hours: Mar 18, 2026, 7:28 PM EDT

TransCode Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Mar '26 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
920624-
Market Cap Growth
535.23%3459.00%-98.85%-75.07%--
Enterprise Value
5.92-3.38-2.660.952.920
Last Close Price
9.5566.084264.96348237.121397088.00-
PE Ratio
--0.05-0.04-0.35-1866.67-
PB Ratio
5.58-1.200.041.831.16-
P/TBV Ratio
3.12-0.420.501.89624.37-
P/FCF Ratio
--0.180.00-0.37-4.30-
P/OCF Ratio
--0.180.00-0.38-4.51-
EV/EBITDA Ratio
-0.220.14-0.05-0.48-
EV/EBIT Ratio
-0.220.14-0.05-0.48-
EV/FCF Ratio
-0.250.15-0.06-0.53-
Debt / Equity Ratio
-00.0200-0.61
Debt / EBITDA Ratio
-0.00-0.02---2.87
Debt / FCF Ratio
-0.00-0.02---4.23
Net Debt / Equity Ratio
-1.992.86-1.41-1.53-1.02-0.37
Net Debt / EBITDA Ratio
0.170.380.120.273.41-1.73
Net Debt / FCF Ratio
0.200.430.130.313.77-2.55
Quick Ratio
1.022.100.791.238.222.05
Current Ratio
1.602.561.281.708.972.05
Return on Equity (ROE)
9155.19%8866.94%-759.85%-148.57%-80.53%103.76%
Return on Assets (ROA)
-272.27%-251.29%-304.42%-122.08%-51.27%-115.35%
Return on Invested Capital (ROIC)
1892.13%1671.49%1633.95%1758.98%2308.94%859.47%
Return on Capital Employed (ROCE)
-502.72%-505.04%-789.40%-157.61%-58.43%-183.48%
Earnings Yield
-309.85%-1997.46%-2244.62%-287.30%-0.05%-
FCF Yield
-165.82%-550.01%-26539.15%-267.96%-23.25%-
Buyback Yield / Dilution
-177.82%-675.32%-23314.00%-0.10%-111.06%-
Updated Sep 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q